BIO CEO Says Prescription Drugs Are Not Too Expensive If you needed any more evidence that Big Pharma is tone deaf to the growing crisis of rising prescription drug prices, look no further than a Tuesday C-SPAN interview with BIO President and CEO Jim Greenwood. During the interview, on C-SPAN’s “Washington Journal” program, Greenwood answers […]
Q2 Earnings: Big Pharma Keeps Living the Good Life While Evading Accountability Drug Makers Sweep Profit Forecasts as Industry Continues to Price-Gouge American Patients Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday following earnings announcements from 12 of the world’s largest brand name drug manufacturers that showed all had […]
Four More Rx Giants Complete the Sweep, Beat Q2 Earnings Forecasts After Hiking Prices Over the past week, CSRxP has been tracking Q2 earnings for the biggest prescription drug manufacturers in the world. Yesterday, four more of these Big Pharma giants – Amgen, Eli Lilly, Merck and Pfizer – completed the sweep by reporting […]
Brand Name Drug Makers Continue to Surpass Q2 Forecasts After Hiking Prices Pharmaceutical giants AbbVie and Sanofi kept the good times rolling for Big Pharma on Friday and Monday, with both besting earnings forecasts and raising outlooks for the remainder of the year. AbbVie reported $8.2 billion in sales, beating estimates of $8.1 billion […]
Three More Drug Makers Top Earnings Expectations in Q2 Today three more price-gouging Big Pharma companies reported better-than-expected earnings in Q2 and raised forecasts for the rest of the year — after engaging in a frenzy of price hikes this year. Bristol-Myers Squibb reported revenues of $6.27 billion – 11 percent higher than predicted […]
Big Pharma Giants Now Three for Three Besting Forecasts After Hiking Prices More Big Pharma giants are reporting earnings this week for the second quarter of 2019. Today GlaxoSmithKline (GSK), one of the five largest drug manufacturers in the world, reported that revenue rose five percent in Q2, beating profit expectations. Sales were about […]
America’s seniors and taxpayers received a huge win today when the administration made the right call to withdraw a proposal, known as the Rebate Rule, from the Department of Health and Human Services (HHS). The Campaign for Sustainable Rx Pricing (CSRxP) was a leading voice raising concerns with the proposed rule, including, among others, its […]
Proposed Bill Would Undermine Fair and Efficient Review Process Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today on the introduction of The Support Technology & Research for Our Nation’s Growth and Economic Resilience (STRONGER) Patents Act of 2019. “Inter partes reviews (IPR) were established by Congress through the America […]
Washington, D.C. – The U.S. Senate Special Committee on Aging held its third hearing on the “Complex Web of Prescription Drug Prices” on Wednesday. Senators from both sides of the aisle called for action to lower drug prices for not only seniors, but all patients, and hit Big Pharma for the industry’s anti-competitive and price-gouging […]
Largest Drug Makers Beat Profit Forecasts While Continuing To Price Gouge Patients Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday following earnings announcements from ten Big Pharma giants that showed they all surpassed profit forecasts for the first quarter of 2019. Drug maker GlaxoSmithKline (GSK) was the latest, announcing […]